CD8A and melanoma: used flow cytometry to examine peripheral blood samples from melanoma patients receiving ICIs and discovered that PD-1 downregulation had the greatest impact on CD3+, CD4+, and CD8+ T cells at all time points after treatment initiation and that CD8+CD38+ T cells and CD8+ effector memory T cells were higher at the time point of AEs (47).